<?xml version="1.0" encoding="UTF-8"?>
<p id="p0025">Novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the (Corona Virus Disease 2019) COVID-19, emerged in Wuhan, Hubei province, China. On 11th March 2020, The World Health Organization (WHO) declared this disease as pandemic [
 <xref rid="bib1" ref-type="bibr">1</xref>]. Chinese Centre for Disease Control and Prevention showed an increased mortality in people with diabetes (2.3% 
 <italic>vs</italic>. 7.3%; overall 
 <italic>vs</italic>. in patients with diabetes respectively) from a report of 72,314 cases of COVID-19 [
 <xref rid="bib2" ref-type="bibr">2</xref>]. People with diabetes and COVID-19 may need special attention and clinical care [
 <xref rid="bib3" ref-type="bibr">3</xref>]. In the absence of any known efficient therapy and because of the situation of a “public-health emergency”, many drugs have been tried recently in the treatment for COVID-19 that includes a low-cost antimalarial drug chloroquine and its derivative hydroxychloroquine (HCQ), along with several other antiviral drugs. Because HCQ has been approved in the treatment of type 2 diabetes in India since 2014 as a third- or fourth-line drug, it would be interesting to research its impact in patients with diabetes, infected with COVID-19.
</p>
